Curis (CRIS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Apr, 2026Executive summary
Annual meeting scheduled for May 19, 2026, to be held virtually, with voting on key proposals including director elections, executive compensation, auditor ratification, and an amendment to increase authorized shares.
Record date for voting is March 23, 2026, with 39,978,693 shares outstanding and each share entitled to one vote.
Proxy materials distributed by mail and email, with multiple voting methods available: internet, phone, mail, or online during the meeting.
Voting matters and shareholder proposals
Election of two Class III directors for three-year terms.
Advisory (non-binding) vote on executive compensation (say-on-pay).
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Approval of amendment to increase authorized shares of common stock.
Approval to adjourn the meeting if more time is needed to solicit votes for the share increase proposal.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board divided into three classes; Class III nominees are Martyn D. Greenacre and Kenneth I. Kaitin, Ph.D.
Majority of board and all committee members are independent under Nasdaq standards.
Board leadership structure separates CEO and Chairman roles for enhanced oversight.
Board committees: audit, compensation, and nominating/corporate governance, each with defined responsibilities and charters.
Directors are expected to attend meetings and participate in ongoing education; all attended at least 75% of meetings in 2025.
Latest events from Curis
- Shareholders will vote on director elections, executive pay, auditor ratification, and a major share increase.CRIS
Proxy filing10 Apr 2026 - Emavusertib delivers deep, durable responses in blood cancers and advances toward registrational trials.CRIS
Corporate presentation1 Apr 2026 - Q4 2025 net income surged on Erivedge sale; PCNSL and CLL studies drive future growth.CRIS
Q4 202520 Mar 2026 - Shareholders to vote on share increase, PIPE-related issuances, and a new equity incentive plan.CRIS
Proxy Filing19 Feb 2026 - Registers 107.7M shares for resale by PIPE investors; no proceeds to company; clinical-stage biotech.CRIS
Registration Filing13 Feb 2026 - Shareholders to vote on major share increase, PIPE-related issuances, and a new incentive plan.CRIS
Proxy Filing9 Feb 2026 - Emavusertib gains EU ODD as Q2 net loss hits $11.8M; cash runway extends into Q1 2025.CRIS
Q2 20242 Feb 2026 - Emavusertib delivers strong early results in NHL and AML, with expansion into solid tumors underway.CRIS
H.C. Wainwright 26th Annual Global Investment Conference 202420 Jan 2026 - Promising IRAK4 inhibitor data in AML and NHL drive pivotal trial plans and partnership interest.CRIS
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026